Business News • PR NewsWire • FDA Approves Tasigna® for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over Gleevec®

FDA Approves Tasigna® for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over Gleevec®

FDA Approves Tasigna® for Newly Diagnosed Chronic Myeloid Leukemia Patients, Data Demonstrate Major Advance Over Gleevec®

EAST HANOVER, N.J., June 17 /PRNewswire/ -- Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in ch

View More : http://www.prnewswire.com/news-releases/fda-approves-tasigna-for-newly-diagnosed-chronic-myeloid-leukemia-patients-data-...

Releted News by prnewswire

U.S. Census Bureau Daily Feature for June 18

AHPA Provides Industry With Practical Information at Seminar on Establishing Identity & Vendor Qualification